Providence Health and Services
  Home  |  Health Plans  |  Providers  |  Programs & Services  |  Hospitals & Clinics  |  Health Info  |  Employment  |  Foundations

Site Search
myProvidence:
Login
Register
 
 

 

Publications: Bernard A. Fox, Ph.D.
 

Chief, Laboratory of Molecular & Tumor Immunology
Robert W. Franz Cancer Research Center

To view related abstracts of these publications, search the PubMed database.

  1. Dienst, SG, MacDonald, R, Toledo-Pereyra, LH, and Fox, BA: Modification of Donor Pretreatment Prolongs Canine Renal Allograft Survival.  Transplantation Proc. 11(2):1465-1466, 1979.
  2. Toledo-Pereyra, LH, Fox, BA, Gordon, DA, and Jennings, J: Lack of Blocking Effect of Chondroitin Sulfate on Lymphocyte Defined Antigens.  Transplantation 27(6):429-430, 1979.
  3. Gordon, DA, Fox, BA, and Toledo-Pereyra, LH: Cell Mediated Immune Response and Cimetidine.  Michigan Academician 12(3):281-288, 1980.
  4. Fox, BA, Westrick, PW, Oh, HK, and Dienst, SG: Effect of Immunosuppression of Murine Responses to Skin Allografts and Concanavalin A; Analysis of T Cell Subsets.  Transplantation Proc. XV(3):1988-1992, 1983.
  5. Fox, BA, Petty, HR: Characterization of a Monoclonal Antibody Defining a Macrophage Activation-Specific Cell Surface Antigen.  Molecular Immunology 21(7): 681-4, 1984.
  6. Fox, BA, Westrick, PW, and Nathanson, SD: Kinetics of the Mixed Lymphocyte Reaction Following Allogeneic Donor Specific Blood Transfusion in C57BL/6 Mice: Transplantation. 40(3):275-278, 1985.
  7. Petty, HR, Fox, BA, Berg, KA, and Francis, JW: A Monoclonal Antibody (BMA-1) Reactive with Murine B Cells as Well as Resident and Elicited But Not Activated Macrophages.  Immunology Letters 15:341-6, 1987.
  8. Fox, BA, and Rosenberg, SA: Heterogeneous Lymphokine-Activated Killer Cell Precursor Populations; Development of a Monoclonal Antibody that Separates Two Populations of Precursors with Distinct Culture Requirements and Separate Target-Recognition Repertoires.  Cancer Immunol. Immunother 29:155-166, 1989.
  9. Fox, BA, Spiess, PJ, Kasid, A, Puri, RK, Mule, JJ, and Rosenberg, SA: In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor infiltrating lymphocytes.  J. Biol. Resp. Mod. 9(5):499-511, 1990.
  10. Fox, BA: New experimental approaches to the adoptive immunotherapy of cancer: Cytokines, gene therapy, oncogenes and transgenic mice.  In:  Basic and Clinical Research on Renal Cell Carcinoma.  Eds. G. Staehler and S. Power.  Springer-Verlag. Berlin, Heidelberg, New York. pg 165-188, 1992.
  11. Nabel, GJ, Chang, AE, Nabel, EG, Plautz, GE, Fox, BA, Huang, L, and Shu, S.  Immunotherapy of malignancy by in vivo gene transfer into tumors.  Human Gene Therapy 3:399-410, 1992.
  12. Wahl, WL , Plautz, GE, Fox, BA, Nabel, GJ, Shu, S, and Chang, AE: Generation of therapeutic lymphocytes after in vivo transfection of tumor with a gene encoding allogeneic class I MHC antigen.  Surgical Forum 63:476-8, 1992.
  13. Nabel, GJ, Nabel, E, Yang, Z, Fox, BA, Plautz, G, Gao-X, Huang, L, Shu, S, Gordon, D, and Chang, AE:  Direct gene transfer with DNA-liposome complexes in melanoma:  Expression, biologic activity, and lack of toxicity in humans.  Proc. Natl. Acad. Sci. USA 90:11307-11 Dec. 1993.
  14. Nabel, GJ, Chang, AE, Nabel, E, Plautz, G, Ensminger, W, Fox, BA, Felgner, P, Shu, S, and Cho, K,:  Immunotherapy for Cancer by Direct gene transfer into tumors.  Human Gene Therapy 5:57-77, 1994.
  15. Nabel, GJ, Fox, BA, Post, L, Thompson, CB, Woffendin, C: A Molecular Genetic Intervention for AIDS - Effects of a Transdominant Negative Form of Rev. Human Gene Therapy 5: 79-92, 1994.
  16. Shu, S, Krinock, RA, Matsumura, T, Sussman, JJ, Fox, BA, Chang, AE, and Terman, DS:  Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J. Immunology 152(3):1277-88, 1994.
  17. Poo, H, Fox, BA, and Petty, HR:  Ligation of CD3 triggers transmembrane proximity between LFA-1 and corticalmicrofilaments in cytotoxic tumor infiltrating T cells: A quantitative resonance energy transfer microscopy study. J. Cellular Physiology 159(1):176-80, 1994.
  18. Plautz, GE, Nabel, EG, Fox, BA, Yang, Z, Jaffe, M, Gordon, D, Chang, A, Nabel, GJ: Direct Gene Transfer for the understanding and treatment of human disease.  Annals of the New York Academy of Sciences, New York, 716: 144-153 (May 31 1994).
  19. Nabel, GJ, Nabel, E, Yang, Z, Fox, BA, Plautz, G, Gao-X, Huang, L, Shu, S, Gordon, D, and Chang, AE:  Molecular Genetic Interventions for Cancer. CSHSQB LIX:699-707, 1994.
  20. Fox, BA, Osterholzer, JJ, Mali, V, Schmogi, M: Trafficking and survival of effector T cells in vivo. in Immunotherapy of Cancer with Sensitized T Lymphocytes. ed. Chang, AE. and Shu, S.  R.G. Landes Company, Austin. pg 91-109, 1994.
  21. Wahl, WL, Strome, SE, Nabel, GJ, Plautz, GE, Cameron, MJ, San, H, Fox, BA, Shu, S, Chang, AE:  Generation of Therapeutic T Lymphocytes after In Vivo Tumor Transfection with an Allogeneic Class I Major Histocompatibility Complex Gene.  J. Immunotherapy 17:1-11, 1995.
  22. Fox, BA, Woffendin, C, Yang, Z, San, H, Kumar, U, Gordon, D, Osterholzer, J, Nabel, GJ: Genetic Modification of Human Peripheral blood Lymphocytes with a Transdominant Negative Form of Rev: Safety and Toxicity.  Human Gene Therapy 6:997-1004, 1995.
  23. Hu, H-M, and Fox, BA. Transfer of Genes Encoding Antigens, Co-Stimulatory Molecules, or Adhesion/Accessory Molecules as a Strategy to Augment the Anti-Tumor Immune Response. Gene Therapy of Cancer.  eds.  Brenner, M.K. and Moen, R.C. Marcel Dekker Inc. New York, pg121-138, 1996. 
  24. Fox, BA, and Nabel, GJ: The potential role of gene transfer techniques in altering the immune response to tumors.  In Immunotherapy and Cancer Vaccines. ed. Dalgleish, A.G., and Browning, M.,  Cambridge University Press, pg300-326, 1996.
  25. Chang, AE, Aruga, A, Cameron, MJ, Sondak, VK, Normolle, DP, Fox, BA, Shu, S: Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and IL-2.  J. Clin. Oncology 15(2) 796-807, 1997.
  26. Fox, BA, Drury, M, Hu, H-M, Huntzicker, EG, Cao, Z, Qie, W and Urba, WJ: Lipofection indirectly increases expression of endogenous MHC class I molecules on tumor cells.  Cancer Gene Therapy 5(5):307-12, 1998.
  27. Hu, H-M, Urba, WJ, and Fox, BA: Gene modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to type 1 cytokine profile.  J. Immunology. 161:3033-3041, 1998.
  28. Winter, H, Fox, BA: Adoptive Cellular Immunotherapy of Cancer.  Current Opinion in Molecular Therapeutics. 1 (1):89-97, 1999.
  29. Chu, Y, Hu, H-M, Winter, H Wood, WJ, Doran, T, Lashley, D, Bashey, J, Schuster, J, Wood, J, Lowe, B, Vetto, JT, Weinberg, AD, Puri, R, Smith, II JW, Urba, WJ, Fox, BA: Examining the immune response in sentinel lymph nodes of mice and men. Eur J Nucl Med, 26(4 Suppl):S50-3, Apr, 1999.
  30. Winter, H, Hu, H-M, Urba, WJ, Fox, BA: Tumor regression after adoptive transfer of effector-T cells is independent of perforin or Fas-Ligand (APO-iL/CD95L). J. Immunology. 163:4462-4472, 1999.
  31. Hu, H-M, Winter, H, Urba, WJ, and Fox, BA: Divergent Roles for CD4+ Helper T Cells in the Priming and Effector Phases of Adoptive Immunotherapy. J. Immunology. 165: 4246-4253, 2000.
  32. Winter, H, Hu, H-M, Urba, WJ, and  Fox, BA: Immunotherapy of Melanoma: A Dichotomy Between the Requirement for IFN-g in Vaccine Induced Antitumor Immunity, but not for Effective Adoptive Immunotherapy1. J. Immunology. 166:7370-7380, 2001.
  33. Meijer, S.L., A.Dols, H-M.Hu, S.Jensen, C.H.Poehlein, Y.Chu, H.Winter, J.Yamada, T.Moudgil, W.J.Wood, T.Doran, L.Justice, B.Fisher, P.Wisner, R. Mehrotra, S. Rosenheim, A.D.Weinberg, R.Bright, E.Walker, R.Puri, J.W.Smith II,W.J.Urba and Fox, B.A; Immunological and Molecular Analysis of the Sentinel Lymph Node: A Potential Approach to Predict Outcome, Tailor Therapy, and Optimize Parameters for Tumor Vaccine Development. J. Clin. Pharmacol. 41:81S-94S, 2001.
  34. Meijer, S.L., Dols, A., Urba, W.J., Hu, H-M, Smith, J.W. II, Vetto, J., Wood, W., Doran, T., Chu, Y, Sayaharuban, P., Alvord, W.G., and Fox, BA: Adoptive cellular therapy with tumor vaccine draining draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells. J. Immunotherapy. 25(4):359-372, 2002.
  35. Hu, HM, Winter, H, Ma, J, Croft, M, Urba, WJ, Fox, BA: CD28, TNF Receptor, and IL-12 Are Critical for CD4-Independent Cross-Priming of Therapeutic Antiumor CD8+ T Cells. J. Immunology 169:4897-4904, 2002.
  36. Hu, HM, Poehlein, CH, Urba, WJ, and Fox BA: Development of Antitumor Immune Responses in Reconstituted Lymphopenic hosts. Cancer Research 62, 3914-3919, Jul 2002.
  37. Poehlein, CH, Hu, HM, Yamada, J, Assmann, I, Alvord, WG, Urba, WJ, Fox, BA: TNF Plays an Essential Role in Tumor Regression after Adoptive Transfer of Perforin/IFN-g Double Knockout Effector T Cells. J. Immunology. 170:2004-2013, 2003.
  38. Jensen, SM, Meijer, SL, Kurt, RA, Urba, WJ, Hu, HM, Fox, BA: Regression of a Mammary Adenocarcinoma in STAT6-/- Is Dependent on the Presence of STAT6-Reactive T Cells. J. Immunology. 170:2014-2021, 2003.
  39. Dols, A, Meijer, Hu, HM, Goodell, V, Disis, ML, von Mensdorff-Pouilly, S, Verheijen, R, Alvord, WG, Smith II, JW, Urba, WJ, Fox, BA: Identification of Tumor-Specific Antibodies in Patients With Breast Cancer Vaccinated with Gene-Modified Allogeneic Tumor Cells. J. Immunotherapy 26(2):163-170, 2003.
  40. Winter, H, Hu, H-M, Poehlein, CH, Huntzicker, E, Osterholzer, JJ, Bashy, J, Lashley, D, Lowe, B, Yamada, J, Alvord, G, Urba, WJ and Fox, BA: Tumor-Induced Polarization of Tumor Vaccine-Draining Lymph Node T Cells to a Type 1 Cytokine Profile Predicts Inherent Strong Immunogenicity of the Tumor and Correlates with Therapeutic Efficacy in Adoptive Transfer Studies. Immunology 108(3): 409-19, 2003.
  41. Smith J.W.II, Walker EB, Fox BA, Haley D, Wisner KP, Doran T, Fisher B, Justice L, Wood W, Vetto J, Maecker H, Dols A, Meijer S, Hu HM, Romero P, Alvord WG, Urba WJ.  Modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol. Apr 15:21(8):1562-73, 2003.
  42. Dols, A, Meijer, SL, Smith II, WJ, Fox, BA, Urba, WJ: Allogeneic breast cancer cell vaccines. Clin Breast Cancer 3 Suppl 4: S173-80, 2003.
  43. Ruettinger, D, Li, R, Urba, WJ, Fox, BA, and Hu, H-M: Evaluation of a preclinical model of bone metastases for Immunotherapy.  Eur. Surg. Res. Jul-Aug;35(4):346-51. 2003.
  44. Ma, J, Urba, WJ, Si, L,Wang, Y, Fox BA, Hu, H-M: Enhanced Protective Anti-Tumor Immunity in Mice Subjected to Sublethal Irradiation and Immune Reconstitution.  Eur. J. Immunol.  33(8):2123-32, 2003.
  45. Dols, A,  Smith II, JW, Meijer, SL, Fox, BA, Hu, H-M, Walker, E, Rosenheim, S, Moudgil, T, Doran, T, Wood, W, Seligman, M,  Alvord, G, Schoof, D, Urba, WJ: Vaccination of women with metastatic breast cancer using a costimulatory gene (CD80)-modified HLA-A2-matched, allogeneic, breast cancer cell line: Clinical and immunological results.  Human Gene Therapy, 14 (11):1117-23 2003.
  46. Hu, H-M, Dols, A, Meijer, SL, Floyd, K, Walker, E, Urba, WJ, Fox, BA:"Immunological monitoring of patients with melanoma after peptide vaccination using soluble peptide/HLA-A2 dimer complexes." J. Immunotherapy 27(1):48-59 2004.
  47. Li R, Ruttinger D, Urba WJ, Fox BA, and Hu H-M: Targeting and Amplification of Tumor Immune Killing Mechanisms by Pro-Smac I. International J. of Cancer. 109(1):85-94 2004.
  48. Nemunaitisl, J, Sterman, D, Jablons, D, Smith II, JW, Fox, B, Maples, P, Hamilton, S, Borellini, F, Lin, A, Morali, S, Hege, K: Granulocyte-Macrophage Colony-Stimulating Factor Gene-Modified Autologous Tumor Vaccines (GVAX) in Non-Small Cell Lung Cancer. J. Natl Cancer Inst.  96(4):326-31, 2004.
  49. Walker, EB, Haley, D, Miller, W, Floyd, K, Wisner, KP, Sanjuan, N, Maecker, H, Romero, P, Hu, HM, Alvord, WG, Smith, JW II, Fox, BA, Urba, WJ: gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells." Clin Cancer Res 10(2): 668-80, 2004.
  50. Meijer, SL, Dols, A, Hu, HM, Chu, Y, Moudgil, T, Wood, Vetto, JT, Smith II, JW, Urba, WJ,  and Fox, BA: Analysis of the Tumor-Specific T cell Response in the Sentinel Lymph Node Draining an Autologous Tumor Vaccine.  Cellular Immunol. 227 : 93-102, 2004.
  51. F Hinds MT, Courtman DW, Goodell T, Kwong M, Brant-Zawadzki H, Burke A, Fox BA, Gregory KW. Biocompatibility of a xenogenic elastin-based biomaterial in a murine implantation model: the role of aluminum chloride pretreatment. J Biomed Mater Res 69A(1):55-64. 2004
  52. Ma. J, Poehlein, C.H., Jensen, S., LaCelle, M.G ., Moudgil, T.M., Rüttinger, D., Haley, D, Goldstein, M ., Smith III, J.W.. Curti, B, Ross, H., Walker, E., Hu, H-M., Urba, W.J., Fox, B.A.  Manipulating the Host Response to Autologous Tumor Vaccines.  Dev. Biol. Basel  116: 93-107, 2004
  53. Fox, BA. Review of - Melanoma vaccines: what we know so far.  Oncology  19(1):112-5. 2005
  54. Friedman, K.M. and Fox, B.A.  The promising future of proteomics in cancer diagnosis and treatment. Eur. J. Gastro and Hep. In press. 2005
  55. Poehlein, CH, Ruttinger, D, Ma, J, Hu, H-M, Urba, WJ, Fox, BA: Immunotherapy for melanoma: the good, the bad, and the future. Curr Oncol Rep. 7(5) 383-92, 2005.
  56. Wang, LX, LI, R, Yang, G, Lim, M, O'Hara, A, Chu, Y, Restifo, NP, Fox, BA, Urba, WJ, and Hu, HM: IL-7 dependent expansion and persistence of adoptively transferred T cells in lymphodepleted mice after vaccination leads to tumor regression and editing. Cancer Research. 65:10569-77, 2005.
  57. Ma, J, Wang, YL, Hu, HM, Fox, BA, Si, LS: Mechanism of augmented anti-tumor immunity in reconstitute lypmphopenice mice immunized with melanoma vaccine. Zhonghua Zhong Liu Za Zhi. 27(12) 708-12, 2005.
  58. Nemunaitis, J, Jahan, T, Ross, H, Sterman, D, Richards, D, Fox, B, Jablons, D. Aimi, J, Lin, A, and Hege, K: Phase 1/2 trail of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Therapy. 13(6):555-562, 2006.
  59. van den Engel NK, Winter H, Ruttinger D, Shau I, Schiller M, Mayer B, Moudgil T, Meimarakis G, Stolte M, Jauch KW, Fox BA, Hatz RA: Characterization of immune responses in gastric cancer patients: A possible impact of H. pylori to polarize a tumor-specific type 1 response? Clin Immunol. Epub 2006, 120(3): 285-96.
  60. Ruttinger D, Winter H, van den Engel NK, Hatz RA, Schlemmer M, Pohla H, Grutzner S, Schendel DJ, Fox BA, Jauch KW: Immunotherapy of lung cancer: an update. Onkologie 2006, 29(1-2):33-38.
  61. He H, Wisner P, Yang G, Hu HM, Haley D, Miller W, O'Hara A, Alvord WG, Clegg CH, Fox BA, Urba WJ, Walker EB: Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med 2006, 4(1):24
  62. Urba, WJ, Meijer, SL, Doles, A, Jensen, SM, Hu, HM, Miller, W. Walker, EB, Romero, P, Fox, BA. J Immunotherapy 2007 (in press).
Home | myProvidence
Notice of Privacy Practices
Site Map | Contact | FAQ


Terms of Use and Privacy Policy | Disclaimer